In our latest episode of the C-Path podcast, “Connecting the Dots Between Type 1 Diabetes and Parkinson’s Disease,” we explore the surprising intersections between these two conditions in recognition of Parkinson’s Awareness Day. Join C-Path CEO Klaus Romero as he moderates a powerful conversation with Diane Stephenson, Vice President of Neurology and Executive Director of the Critical Path for Parkinson’s Consortium, and Joe Hedrick, Executive Director of the Type 1 Diabetes Consortium. Together, they share key insights from their collaborative work at C-Path, revealing how cross-disease learnings, patient perspectives, and data-driven strategies are helping to accelerate progress in drug development.
Key Highlights from the Episode:
- Targeted Focus: Amongst its 20+ dedicated focus areas, C-Path concentrates on improving drug development specifically for indications such as type 1 diabetes and Parkinson’s disease.
- Patient Involvement: The voices of patients are central, with their experiences actively informing research and clinical outcomes.
- Biomarker Utility: Biomarkers significantly enhance the understanding of disease progression, particularly in detecting conditions before symptomatic onset.
- Staging Concepts: Both T1DC and CPP utilize disease staging to quantify progression and risk, offering a proactive approach to treatment.
- Collaboration is Key: The involvement of interdisciplinary stakeholders, including industry, academia, and regulatory agencies, is crucial for effective drug development.
- Data-Driven Decisions: Employing robust data models eliminates guesswork in clinical trials, optimizing design and execution.
- The Neutral Convener: C-Path acts as a neutral broker, providing objective analyses to enhance regulatory decision-making and patient safety.
